ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville,

Slides:

Advertisements

Similar presentations

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.

Advertisements

Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

Statistical Evaluation of Dissolution for Specification Setting and Stability Studies Fasheng Li Associate Director, Pharmaceutical Statistics Worldwide.

Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy

Finished Pharmaceutical Product Specifications

1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,

Batch Reworking and Reprocessing

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

World Health Organization

Determine impurity level in relevant batches1

1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.

Stefan Franzén Introduction to clinical trials.

Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.

Assessing Quality-by-Design A CMC Review Perspective

Conducting the IT Audit

Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)

September 2006PQRI Training Course1 Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables VIII. Quality Control and.

Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.

ITFG/IPAC Collaboration OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.

Basic Principles of GMP

Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.

Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.

Cellular Products for Cardiac Diseases Dwaine Rieves, MD Center for Biologics Evaluation and Research FDA Perspective on:

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Stefan Franzén Introduction to clinical trials.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.

1 Impurities: Positions of the regulatory authorities (like FDA and EMA) worldwide Dr. Christian Zeine, Warsaw, Nov 18, 2014 Science for a safer world.

FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.

Total Excipient Control (TEC) Tools for Managing Excipient Quality A Pathway to Increased Patient Safety David R. Schoneker Vice Chair – Maker and Distributor.

Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update Moheb M. Nasr, Ph.D. Office of New Quality Assessment (ONDQA,

Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products: Work of the ITFG/IPAC-RS Collaboration Presented by Cynthia.

1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.

Overview of FDA's Regulatory Framework for PET Drugs

1 Basis of the Proposed Tactical Plan for a QbD approach for Quality Control and Assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director,

Molecule-to-Market-Place Quality

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

1 Is it potent? Can these results tell me? Statistics for assays Ann Yellowlees PhD Quantics Consulting Limited.

1 Subcommittee Report: Orally Inhaled and Nasal Drug Products (OINDP) Wallace P. Adams, Ph.D. OPS/CDER/FDA Advisory Committee for Pharmaceutical Science.

General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.

1 Dose Content Uniformity for Aerosol Products Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD.

1 PTIT for DCU of OINDP: Approaches to Resolution of Identified Issues Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 21.

ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

ITFG/IPAC Collaboration BA/BE Technical Team ITFG/IPAC TECHNICAL TEAM: BA/BE IN VITRO AND IN VIVO TESTS Presented by: Stephen Farr, PhD 26 April 2000 Rockville,

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team ITFG/IPAC TECHNICAL TEAM: SUPPLIER QUALITY CONTROL (QUALIFICATION) Presented by: Gordon.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15,

Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.

VICH Guidelines: Stability Testing of New Veterinary Drug Substances and Medicinal Products Mai Huynh U.S. FDA Center for Veterinary Medicine Washington.

ITFG/IPAC Collaboration CMC Leachables and Extractables Technical Team ITFG/IPAC TECHNICAL TEAM: CMC LEACHABLES AND EXTRACTABLES Presented by: Kaushik.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.

INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.

The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Worldwide ENC Database Working Group

NEW DRUG APPLICATION.

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

CTD Content Management

ICH-GCP Avinash Kondawar M. Pharm Lead CRA

Company Registration: Procedure that one needs to follow Company Registration: Procedure that one needs to follow

Percentage Key Message

Quality guidelines on impurities

Quality guidelines on impurities

SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center

Presentation transcript:

ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville, MD

ITFG/IPAC Collaboration CMC Specifications Technical Team CMC SPECIFICATIONS TECHNICAL TEAM Focus on Dose Content Uniformity (DCU) Particle Size Distribution (PSD)

ITFG/IPAC Collaboration CMC Specifications Technical Team ICH: HARMONISATION OINDP are amenable to the principles set forth by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The ICH Harmonised Tripartite Guideline on "Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances" (Q6A) provides a process for establishing specifications.

ITFG/IPAC Collaboration CMC Specifications Technical Team ICH Q6A: SPECIFICATIONS “ The justification [of specifications] should refer to relevant development data, pharmacopoeial standards, test data for drug substances and drug products used in toxicology and clinical studies, and results from accelerated and long term stability studies, as appropriate. Additionally, a reasonable range of expected analytical and manufacturing variability should be considered. It is important to consider all of this information.” (62 Fed Reg 62892)

ITFG/IPAC Collaboration CMC Specifications Technical Team DCU Hypothesis: The current state of OINDP technology may not allow general compliance with the DCU specifications in the draft FDA CMC Guidances. To date, more than 12 companies have initiated the process to collect a world-wide blinded database of more than 45 products to examine actual DCU capability of OINDP Initial assessment by July 31

ITFG/IPAC Collaboration CMC Specifications Technical Team DCU ITFG/IPAC position: The specifications in the draft Guidances should be based upon sound statistical practices such that they can be translated into a quality requirements. Investigate, using database, alternate DCU specifications ICH Q4 (Pharmacopoeial Harmonisation) draft proposal Dr. Walter Hauck's Approach ISO Approach Other Approaches

ITFG/IPAC Collaboration CMC Specifications Technical Team PSD To date, more than 12 companies have initiated a process to collect a world-wide blinded database of more than 40 products to examine actual PSD capability of OINDP Initial assessment by July 31 Purpose of PSD survey Examine the relevancy of the mass balance requirement as a product specification versus system suitability requirement. Investigate if fewer than 3-4 stage groupings can provide equivalent control.